About Haemonetics
Haemonetics is a company based in Braintree (United States) founded in 1971. The company has 3,020 employees. Haemonetics has completed 9 acquisitions, including Arryx, Attune Medical and Cardival Medical. Haemonetics offers products and services including Plasma Collection Systems, BloodTrack Software, and SafeTrace Tx. Haemonetics operates in a competitive market with competitors including VISIE, Vetex Medical, MediSieve, Sisu Global Health and Immutrix Therapeutics, among others.
- Headquarter Braintree, United States
- Employees 3,020
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website haemonetics.com
- Social LinkedIn X Facebook
- Legal Name Haemonetics Corporation
Associated legal entities of Haemonetics
Haemonetics operates through Haemonetics Healthcare India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Haemonetics Healthcare India Private Limited CIN U33100KA2013PTC068103 | Active | 06 Mar 2013 | Bangalore, Karnataka | ₹0.8 Cr | – | 2 | View details |
Products & Services of Haemonetics
Haemonetics offers a comprehensive portfolio of products and services, including Plasma Collection Systems, BloodTrack Software, and SafeTrace Tx.
Tools for efficient plasma yield and donor experience enhancement.
Platform for blood inventory and safety management.
Software for blood center operations and traceability.
Funding Insights of Haemonetics
- Total Rounds 3
- Last Round Grant — $3.8M
- First Round $180,000
(Jan 2012)
- Investors Count 1
All 3 funding rounds of Haemonetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Haemonetics
Haemonetics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Haemonetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Haemonetics Healthcare India Private Limited (Haemonetics)
Haemonetics Healthcare India Private Limited is the primary company behind Haemonetics. The board of Haemonetics Healthcare India Private Limited currently have 2 directors; the longest-serving is Ujjwal Sharma, appointed in 2018. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ujjwal Sharma DIN 02887964 | Director | 15 Mar 2018 | 8 yrs 6 mo | Haemonetics Healthcare India Private Limited |
| Pushkar Godkar DIN 10040075 | Additional Director | 14 Feb 2023 | 3 yrs 7 mo | Haemonetics Healthcare India Private Limited |
People of Haemonetics
396 people are tracked at Haemonetics (93 in leadership, 8 in board & advisors, 295 in team); the tracked headcount is 3,020.
| Name | Role | Group |
|---|---|---|
Chris Simon | CEO | Leadership |
Michelle L. Basil | Executive Vice President & General Counsel | Leadership |
Omar Sabbagh | General Manager Mea, CEE And Nordics | Leadership |
Carolyn Forrest | Director Qs, Europe | Leadership |
Rocco Volpe | Vice President Finance Global Mfg & Supply Chain | Leadership |
Jan Hartmann | SVP & Chief Medical Officer | Leadership |
Jessica McShane Lapinski | Global Director Environment Health & Safety/ Facilities And Real Estate | Leadership |
Falgun Patel | Vice President Global Manufacturing & Distribution Quality Assurance | Leadership |
Laurie Miller | Senior Vice President & Chief Human Resources Officer | Leadership |
Alan Mueller | Director, Global Marketing – Interventional | Leadership |
Darrell Thomas | IT Director, Manufacturing & Supply Chain | Leadership |
James C. D’Arecca | Executive Vice President & Chief Financial Officer | Leadership |
Kerri DiPietro | Senior Vice President, Global Quality Assurance | Leadership |
Seth Kasper | Director Of Disposable Devices, Research And Development | Leadership |
Kevin Paszkewicz | Director, Global Procurement Operations | Leadership |
Roy Galvin | President, Global Plasma & Blood Center | Leadership |
Kenneth Dussinger | Sr. Director Global Operations | Leadership |
Paolo Ghislandi | Head Of Technical Product Management Instruments And Head Of Production Instruments | Leadership |
Gwen Drain | Senior Director, Human Resources | Leadership |
Belinda Sissom | Director Global Trade & Customs Compliance | Leadership |
376 more people are available in the full profile.
Complete people profiles for Haemonetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Haemonetics
Haemonetics is a publicly listed company on the NYSE with ticker symbol HAE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 May 1991
- Listed onNYSE: HAE
- Listed entityHaemonetics Corporation
- Exchange sectorHealth technology
- ISINUS4050241003
- Share price$119.47 (+17.46% on the day) · 2026-10-08
- Market capitalisation$5.44B
- Price to earnings58.3
- EPS (diluted, trailing year)$2.05
- Volume (last session)2,775,910
Financials of Haemonetics
Figures of Haemonetics Healthcare India Private Limited, the primary company behind Haemonetics, for FY 2024. Revenue was ₹0.79 Cr (-7% year on year). Net profit was ₹0.03 Cr (4% margin). EBITDA was ₹0.04 Cr (5% margin). Revenue has grown at a compounded annual rate of +8% over three years and -7% over five years.
- ₹0.79 CrRevenue · FY 2024 · -7% YoY
- ₹0.03 CrNet profit · 4% margin
- ₹0.04 CrEBITDA · 5% margin
- ₹0.01 CrPaid-up capital
- +8%Revenue CAGR, 3 years
- -7%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.33B | $97.3M | $356.3M |
| 2024 | $1.36B | $167.7M | $337.9M |
| 2023 | $1.31B | $117.6M | $305.4M |
| 2022 | $1.17B | $115.4M | $260.5M |
| 2021 | $993.2M | $43.4M | $209.0M |
Balance sheet, profit and loss, cash flow and ratios of Haemonetics Healthcare India Private Limited are on its company page.
Detailed financial statements for Haemonetics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Haemonetics
Haemonetics has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Arryx, Attune Medical and Cardival Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bioabsorbable implants and delivery systems for arteriotomy closure are developed. | vivasuremedical.com | Galway, Ireland | 2009 | Jan 2026 | •••• | |
Patient temperature is modulated via esophageal cooling devices. | attune-medical.com | Chicago, United States | 2009 | Mar 2024 | $160M | |
Optical sensors are manufactured for oil, gas, and healthcare sectors. | opsens.com | Quebec, Canada | 2003 | Oct 2023 | •••• | |
A device for vascular access management is developed. | cardivamedical.com | Santa Clara, United States | 2002 | Jan 2021 | $510M | |
Provider of device for coagulation diagnostic | clot.pro | Munich, Germany | 2017 | Apr 2020 | •••• | |
Developer of a device for blood collection | hemerus.com | Saint Paul, United States | 2001 | Apr 2012 | $27M | |
Information management software and services are supplied to healthcare providers. | globalmedtech.com | Lakewood, United States | 1989 | Feb 2010 | $60M | |
A suite of applications to track, allocate, release and dispense hospital blood units | neoterictech.com | Vancouver, Canada | 1997 | Apr 2009 | •••• | |
Blood management solutions are provided for healthcare applications. | arryx.com | Chicago, United States | 2000 | Jun 2006 | •••• |
Complete acquisition details for Haemonetics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Haemonetics
13 dated milestones of Haemonetics across 55 years, from founding to its latest funding, stage changes and deals.
- Founded Haemonetics is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Arryx.
- Acquisition Acquires Neoteric Technology.
- Acquisition Acquires Haemonetics.
- Funding First funding round of $180K.
- Acquisition Acquires Hemerus Medical.
- Acquisition Acquires ClotPro.
- Acquisition Acquires Cardival Medical.
- Funding Latest funding round, Grant, of $3.8M.
- Acquisition Acquires OpSens.
- Acquisition Acquires Attune Medical.
- Acquisition Acquires Vivasure Medical.
Competitors of Haemonetics
Haemonetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as VISIE, Vetex Medical, MediSieve, Sisu Global Health and Immutrix Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| visievision.com | 2017 | Austin, United States | $12.71M | – | Provider of 3D intraoperative imaging technology for orthopedic, neuro, and spine surgery | |
| vetexmedical.com | 2016 | Galway, Ireland | – | – | Catheters for venous clot management and removal are developed. | |
| medisieve.com | 2014 | London, United Kingdom | $4.18M | 12 | Magnetic therapy is developed to treat blood-borne diseases. | |
| sisuglobal.health | 2014 | Baltimore, United States | – | – | Intraoperative autotransfusion devices are developed and provided. | |
| immutrix.com | 2009 | Rapid, United States | $14.02M | – | Blood cleansing treatment device | |
| scinovia.com | 2014 | Durham, United States | $6.91M | 10 | Augmented-reality surgical cameras for blood flow visualization are developed. | |
| haermonics.com | 2015 | Amsterdam, Netherlands | $4.41M | – | Postoperative pericardial drainage and flushing system is developed. | |
| procellsi.com | 2015 | Canton, United States | – | – | Develops medical devices for intraoperative blood recovery and conservation. | |
| i-sep.com | 2015 | Nantes, France | $3.61M | – | Cell salvage solutions for autologous blood transfusion during surgery |
Detailed competitors of Haemonetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Haemonetics
The website of Haemonetics (haemonetics.com) receives about 50.5K visits a month.
- Monthly visits50.5K
▲ 39.5% vs previous month
Websites whose visitors overlap most with Haemonetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
plasmacare.com | plasmacare.com | 100% | – | – | – |
| immucor.com | 92% | 2.5K | #5,047,876 | View details | |
| hologic.com | 86% | 185.1K | #258,622 | View details | |
| terumobct.com | 85% | 56.6K | #599,470 | View details | |
| fenwalinc.com | 84% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for Haemonetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Haemonetics
Complete news archive for Haemonetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Haemonetics
10 companies that operate in the same segment as Haemonetics (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
IVD for hemostasis characterization | 2004 | Charlottesville, Virginia, United States | USD 24.92 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Haemonetics
Haemonetics was founded in 1971 and raised its 1st funding round 41 years after it was founded.
Haemonetics is headquartered in Braintree, United States. It is registered at Braintree, Massachusetts, United States.
Chris Simon is the current CEO of Haemonetics.
Haemonetics has 3,020 employees.
The primary company behind Haemonetics, Haemonetics Healthcare India Private Limited, reported revenue of ₹0.79 Cr for FY 2024, down 7% year on year.
Haemonetics was founded in 1971 and is based in Braintree, United States. Operations focus on the hematology sector within the medical industry, where products and solutions are developed for blood management and related procedures. Offerings include SafeTrace for transfusion tracking in blood banks, Persona as a plasma collection system integrated with the NexSys PCS platform, and VASCADE for arterial and venous closure to limit risks in interventions.
Haemonetics's top competitors include VISIE, Vetex Medical and Sisu Global Health.
Haemonetics offers Plasma Collection Systems, BloodTrack Software, and SafeTrace Tx.
Yes, Haemonetics is publicly traded on NYSE under the ticker symbol HAE.
Haemonetics has made 9 acquisitions, including Arryx, Attune Medical, and Cardival Medical.
Haemonetics has 1 investor. Key investors include HHS.
Haemonetics operates through Haemonetics Healthcare India Private Limited.